Porton Slovenia-Porton Pharma Solutions

In March 2025, Porton Pharma Solutions Ltd. was honored with the "Global Small Molecule API Award" at the 14th Outsourced Pharma CDMO Leadership Awards, recognizing its exceptional end-to-end services across the global small molecule drug lifecycle. This award reaffirms Porton's outstanding performance in the CDMO sector for pharmaceutical R&D and manufacturing worldwide.

As a global CDMO serving global innovative pharmaceutical companies and research institutions, Porton has an extensive experience in research and manufacturing services, especially in the field of PROTAC drug development. Porton is committed to the development and production of PROTAC oral formulations and provides customers with comprehensive, reliable, fast, and compliant one-stop services, to meet customers' supply chain needs and facilitating the commercial success of their products from research and development to order fulfillment.

March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.

Continuous reaction can effectively solve the problem of "amplification effect" in batch processes from research and development to pilot testing, and then again to commercial production. Porton’s continuous reaction capabilities include low-temperature lithiation reaction, ozone oxidation reaction, nitrification reaction, high-temperature reaction, and organic azide reaction, etc., which can achieve process development and technology transfer from research and development to production application. 

Stay connected with Porton’s latest updates, insights, and opportunities through our Porton Monthly Newsletter. This comprehensive publication keeps you informed on key developments across various domains, ensuring you never miss important information.

This white paper details our extensive capabilities in Analytical Research and Development (R&D) and Quality Control (QC) for pharmaceutical drug development. It highlights our expertise in method development, structure elucidation, and method troubling.  Our goal is to ensure the highest standards of quality and efficiency in drug development and manufacturing.

Stay connected with Porton's latest updates, insights, and opportunities through our Porton Monthly Newsletter. This comprehensive publication keeps you informed on key developments across various domains, ensuring you never miss important information.

Antibody drug conjugates (ADCs) have seen significant breakthroughs and reached numerous milestones since 2000 when the first ADC was approved by the FDA and have shown great promise for the treatment of cancer. First generation ADCs were designed to use the affinity of an antibody towards a specific cellular target to bring the cytotoxic payload to the tumor, for example. However, some level of off-target toxicity was often seen with many ADCs because other cellular interactions could occur prior to the payload physically reaching its intended target or the payload could cleave off. These events could lead to unintended death of non-cancerous cells.

Chongqing, China – As the wheel of time turned to mark two extraordinary decades, Porton Pharma Solutions, one of the global leaders in Contract Development and Manufacturing Organization (CDMO) services, recently celebrated its 20th anniversary with a grand celebration in Chongqing, China. Global partners and industry leaders gathered to honor this pivotal milestone, celebrating Porton’s journey from its humble beginnings to a trusted enabler of global healthcare innovation.

Drug discovery is an exceedingly complex process. Discovering a new chemical entity is in itself a huge accomplishment, which is often possible only after almost two decades of hard experimental work as well as advanced simulation efforts. Therefore, the next stage of the process, determination of toxicity becomes even more crucial as most new chemical entities (NCE) are disqualified if the NCE shows a potential toxic effect, despite any possible therapeutic effect.

June 5, 2025, Chongqing — On the 54th World Environment Day, Porton Pharma Solutions Ltd. (Porton) officially announced its 2030 sustainability targets, highlighting its actions in response to the global sustainable development initiative and determination to transition into a greener future.

The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.

Stay connected with Porton’s latest updates, insights, and opportunities through our Porton Monthly Newsletter. This comprehensive publication keeps you informed on key developments across various domains, ensuring you never miss important information.

Antibody Drug Conjugate (ADC) CDMO Services As a subsidiary of the globally recognized CDMO——Porton Pharma Solutions, Porton Biologics CDMO Platform is designed to provide one-stop drug development and manufacturing services for antibodies and antibody drug conjugates (ADCs).

Chongqing, China, June 13, 2025 - Porton Pharma Solutions Ltd. (Porton) today announced that its Changshou site, a flagship site for small molecule API manufacturing, has been awarded a gold medal in the latest EcoVadis sustainability rating, ranking in the top 5% of all participating companies. This achievement not only represents a strong endorsement of Porton’s long-term practices in sustainable development, but also highlights its responsibility in the global pharmaceutical industry chain.

With four major R&D platforms including peptides, oligonucleotides, high-performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.

Recently, Frost & Sullivan released the “2025 China Pharmaceutical CDMO Industry Insight Blue Book”, a comprehensive analysis of the evolution and strategic trajectory of China’s pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. Rooted in an in-depth examination of market dynamics, technological innovation, and global competitiveness, the report elucidates how China’s CDMO industry is reshaping the global pharmaceutical value chain through specialized services, operational agility, and cutting-edge capabilities. As an industry-leading CDMO enterprise, and owing to its 20 years of unwavering commitment to innovation and breakthroughs, Porton Pharma Solutions has been successfully featured as a representative Chinese company in the Blue Book as a typical case study.

Porton Pharma Solutions is a top global CDMO. It has advanced manufacturing facilities in the US, EU, and China, all following strict R&D and GMP standards. The company provides innovative, reliable, and customer-focused CDMO solutions for various products, including small molecules, tides, biologics, conjugates (such as ADCs, AOCs, PDCs, RDCs), and advanced therapy medicinal products, covering all stages from preclinical research to commercial production.

With 18 sites worldwide, Porton offers quick client support. It has over 4,200 employees, including more than 1,200 R&D and technical experts, driving innovation and maintaining high operational standards. Its production capacity is about 2,200 m³, meeting different needs. Having served over 1,200 global clients and handled over 4,000 milestone projects, Porton demonstrates strong business sense and an excellent reputation. In 2024, it achieved $424 million in revenue.

Stay connected with Porton's latest updates, insights, and opportunities through our Porton Monthly Newsletter. This comprehensive publication keeps you informed on key developments across various domains, ensuring you never miss important information.

✔️ Comprehensive Support: We cover every stage of hashtag#PROTAC drug development.
✔️ Global Standards: Adhering strictly to international norms ensures quality and reliability.
✔️ Problem Solvers: Tackling drug development issues.

The New Modality Capacity Upgrade Ceremony was successfully held in Fengxian, Shanghai, China. Attendees included Mr. Weng Jun, Vice General Manager，Shanghai Hangzhou Bay Economic & Technological Development Co., Ltd., Mr. Bai Yinchun, COO and Senior Vice President of Porton, Ms. Pi Wei, Vice President and Board Secretary of Porton, Ms. Meng Fan, Deputy General Manager of the Sales & Marketing Center of Porton, and Mr. Xie Lihua, Head of the Synthetic Macromolecules Service Department. Together, they witnessed this significant moment of enhancing the production capacity for new modalities at the Fengxian site.

1. Process Design, Route Scouting, Development and Optimization for APIs and Intermediates2. non-GMP and GMP Manufacturing for APIs and Intermediates, pre-clinical to Commercial
3. Pre-formulation Research and Process Development & Optimization
4. GMP Manufacturing for Drug Products, from Pre-clinical to Commercial Batches
5. Comprehensive Analytical R&D and Quality Control 
6. IND/NDA Dossier and CMC Solutions

Recently, Dr. Yuriy Abramov and Dr. Jian Wang from Porton’s team of global chemical engineering and technology published a Communication paper titled "Is It Salt, Cocrystal, or Continuum? Successes and Limitations of Computationally Efficient Periodic System Calculations" in Crystal Growth & Design, the American Chemical Society journal. This peer-reviewed journal focuses on publication of new research results in theoretical and experimental studies of the physical, chemical, and biological phenomena and processes related to the design, growth, and application of crystalline materials. The topic of this publication was invited to be shared at the 2024 Crystal Engineering Gordon Research Conference - a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge novel research.

Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.

Porton has a professional technology platform and an experierced team to provide global clientswith CMC solutions for radiopharmaceutical precursors and colodrugs. We are committed tobecoming the leading RDC CDMO company in China.

At Porton, we're passionate about transforming ideas into reality with our customer-centric and innovative CDMO solutions. With facilities across the US, EU, and CN, we offer reliable support for Small Molecules, Tides, Biologics, and Conjugates (ADCs, AOCs, PDCs) from pre-clinical to commercial stages.

The Building Block for Conjugates(Antibody & Payload-Linker)Catalog ProductsOne Stop CDMO Services for Conjugate Products

In March 2025, Porton Pharma Solutions Ltd. was honored with the "Global Small Molecule API Award" at the 14th Outsourced Pharma CDMO Leadership Awards, recognizing its exceptional end-to-end services across the global small molecule drug lifecycle. This award reaffirms Porton's outstanding performance in the CDMO sector for pharmaceutical R&D and manufacturing worldwide.

The Building Block for Tides(Peptides & Oligonucleotides)

March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.

Porton Pharma Solutions, a global company with R&D, and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, AOCs, PDCs, etc.) from pre-clinical to commercial.